We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
May 15, 2025
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
Crinetics will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL.
May 12, 2025
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and an aggregate of 101,800 restricted stock unit awards to 35 new non-executive employees.
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- ACTH-dependent Cushing’s syndrome
- Congenital adrenal hyperplasia (CAH)
- Hyperparathyroidism
- Polycystic kidney disease
- Graves’ disease
- TED
- Diabetes
- Obesity
- Hyperinsulinism
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly
Discovery | IND-enabling | Phase 1 | Phase 2 | Phase 3 | Approved |
---|---|---|---|---|---|
Acromegaly